Determining the Activity of Imipenem/Relebactam Plus Aztreonam Against Constitutive Pseudomonas -Derived Cephalosporinase- and Metallo-β-Lactamase-Producing Pseudomonas aeruginosa in a Hollow Fiber Infection Model
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Abstract Background Few treatment options exist for serious infections caused by metallo-β-lactamase (MBL)-producing Pseudomonas aeruginosa. This study evaluated imipenem/relebactam (I/R) plus aztreonam (ATM) against Pseudomonas-derived cephalosporinase (PDC)- and MBL-producing P. aeruginosa in a hollow fiber infection model, with ceftazidime/avibactam (CZA) plus ATM as a comparator. Methods Two isogenic PDC- and MBL-producing P. aeruginosa isolates (MB10480: IMP-1; MB10620: VIM-1) were studied at a starting inoculum of ∼8 log10 CFU/mL over 96 hours. Humanized I/R exposures were evaluated alone and with extended-infusion ATM (1.5 g every 6 hours [q6h], 2 g q8h, and 2 g q6h), with CZA plus ATM (2 g q6h) as a comparator. Combinations were tested in triplicate, and ATM/relebactam or ATM/avibactam minimum inhibitory concentrations (MICs) were assessed at 96 hours. Results For both MB10480 (ATM/relebactam MIC: 8/4 mg/L) and MB10620 (4/4 mg/L), monotherapy arms mirrored the growth control. Both I/R plus ATM and CZA plus ATM produced early synergy (≥2 log10 CFU/mL reduction relative to the most active monotherapy) with >1 log10 CFU/mL killing relative to the starting inoculum at 24 hours, followed by regrowth, with bacteriostasis observed at 96 hours across regimens. However, bacterial counts at 96 hours were lowest with I/R plus ATM 2 g q6h. Two colony morphologies were recovered, and retested MICs were occasionally, but not consistently, elevated. Conclusions Both I/R plus ATM and CZA plus ATM showed early synergy against PDC- and MBL-producing P. aeruginosa, but regrowth occurred with all regimens. Higher-dose ATM with I/R provided more durable suppression, though persistence remained common, underscoring the need to better define dosing and mechanisms of regrowth.
Fields of Study & Subjects
Antibiotic Resistance in Bacteria
Antibiotics Pharmacokinetics and Efficacy
Infections and bacterial resistance
Publication details
- Journal / source
- Open Forum Infectious Diseases
- Volume
- 13
- Issue
- 4
- Pages
- ofag172–ofag172
- Publication date
- 24 March 2026
- Language
- EN